Tirzepatide 3-month results: what the studies actually show

What did @christine.york2 actually say?

Honestly? Not much. The transcript is: "Check this out. Okay. I look good. Okay. On the street and I got my swag on. Okay. Get the." That's it. There are no dosing claims, no mechanism explanations, no before-and-after stats. The video's substance lives entirely in the hashtags: #tirzepatidecompound, #tirzepatideweightloss, #zepbound, #glp1sideeffects. The implicit claim being made here is visual. She's saying she lost weight over three months, she looks good, and tirzepatide is the reason. Whether that's accurate depends entirely on context we don't have.

That framing matters. When someone pairs a confident "I look good" with a compounded tirzepatide hashtag and a 3-month timeline, the audience reads a testimonial even if none is technically spoken. That's how health content works on TikTok, and it's worth being honest about that.

Does the science back this up?

The general premise, that tirzepatide can produce meaningful weight loss in roughly three months, is well-supported. But "I look good" is not a clinical outcome, and compounded tirzepatide is not the same product as brand-name Zepbound or Mounjaro.

The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) found that tirzepatide at 15 mg weekly produced an average 22.5% reduction in body weight over 72 weeks in adults with obesity. At 12 weeks, weight loss was already statistically significant but far below the endpoint figures. A 3-month window is real but early. Most participants in SURMOUNT-1 were still titrating doses at that point.

Separately, the FDA has not approved compounded tirzepatide as equivalent to Zepbound. The agency has stated explicitly that compounded drugs are not FDA-approved and may differ in safety and efficacy. Using the #tirzepatidecompound hashtag alongside #zepbound in the same post blurs that line in a way patients should notice.

What did they get wrong (or right)?

Credit where it's due: she didn't make any bogus mechanistic claims, didn't recommend a dose, didn't say tirzepatide "cures" anything. In the world of GLP-1 TikTok, that's actually a low bar that a lot of creators fail to clear, and she clears it.

What's missing is any acknowledgment of side effects, which is notable given that #glp1sideeffects is literally one of her own hashtags. The SURMOUNT-1 trial reported that 82.7% of participants on tirzepatide experienced gastrointestinal adverse events, including nausea, diarrhea, and vomiting. These aren't rare edge cases. For a video positioned as a 3-month results update, skipping that entirely is a real gap.

The bigger issue is the compounded tirzepatide framing. Compounded versions are produced under different manufacturing conditions, may use different salt forms, and are not subject to the same FDA review. Stacking that next to #zepbound implies equivalency. It doesn't exist.

What should you actually know?

Three months on tirzepatide is a starting point, not a finish line, and results vary significantly based on dose, adherence, diet, and individual metabolic response. The visual confidence in this video is real, but it's a sample size of one.

If you're considering compounded tirzepatide specifically, the FDA issued a statement in 2024 clarifying that compounded tirzepatide is not the same as Zepbound or Mounjaro and that patients should be aware of the distinction. The agency also noted concerns about compounded versions using tirzepatide base rather than tirzepatide monohydrate, the form used in approved products.

GLP-1 medications require medical supervision, titration protocols, and ongoing monitoring. A TikTok confidence check is not a treatment plan. If a video makes you want to start or switch a medication, that conversation belongs with a licensed provider who has access to your full medical history, not a comment section.